Onkológia 1/2021

Current indications of CAR T-cell therapy

Relapsed or refractory aggressive B-cell lymphoma, and relapsed acute lymphoblastic B-cell leukemia, have a dismal prognosis in most cases. Treatment with chimeric antigen T-cell therapy represents hope for potential long-term remission. Careful patient selection is necessary due to the risk of severe adverse effects of this therapy. Early consideration of the indication is one of the key factors of the therapy’s success, often concerning aggressive disease and the process of drug approval and manufacturing. We discuss indications of CAR T-cell therapy, essential examinations before approval of the indication and administration of CAR T-cell as well as prognostic factors supporting an optimal selection of patients suitable for this therapy.

Keywords: CAR T therapy, acute lymphoblastic leukemia, diffuse large B-cell lymphoma